Rituximab for Pediatric Central Nervous System Inflammatory Disorders in Alberta, Canada
Rituximab for Pediatric Central Nervous System Inflammatory Disorders in Alberta, Canada
About this item
Full title
Author / Creator
Publisher
New York, USA: Cambridge University Press
Journal title
Language
English
Formats
Publication information
Publisher
New York, USA: Cambridge University Press
Subjects
More information
Scope and Contents
Contents
Early and effective treatment of central nervous system (CNS) inflammatory disorders is vital to reduce neurologic morbidity and improve long-term outcomes in affected children. Rituximab is a B-cell-depleting monoclonal antibody whose off-label use for these disorders is funded in the province of Alberta, Canada, by the Short-Term Exceptional Drug...
Alternative Titles
Full title
Rituximab for Pediatric Central Nervous System Inflammatory Disorders in Alberta, Canada
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2771086009
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2771086009
Other Identifiers
ISSN
0317-1671
E-ISSN
2057-0155
DOI
10.1017/cjn.2023.16
